dNovo is a Silicon Valley-based startup focused on solving the aging problem by developing a potential cure for hair loss through direct reprogramming technology to generate personalized hair stem cells. The company aims to transform regenerative medicine by creating new stem cells from sources like skin and blood.
Subscribe to see dNovo’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
dNovo is a healthcare services company headquartered in United States. It has raised at least $45M across the 2 funding rounds on record. Its most recent funding round raised $3M in January 2022.
As of 16 November 2026. Source: Xcout Intel.
At least $45M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $3M | 8 named | |
| Series B | $42M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 12 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of dNovo's closest competitors — see the full list of competitors and alternatives →
Conception Holdings, Inc. develops stem cell technology and computational platforms to generate functional human eggs in the lab through in-vitro gametogenesis. The company aims to expand reproductive options for individuals facing biological and medical fertility limits by recreating key steps of human development.
HexemBio is a health technology company developing regenerative therapies based on a Synthetic Human Yolk Sac technology designed to rejuvenate aging blood stem cells. Its lead program focuses on improving bone marrow transplant outcomes for blood cancer patients to extend healthy lifespan.
eGenesis, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing advanced genome-editing solutions. The company utilizes its proprietary platform to work on xenotransplantation and address organ shortages for human patients.
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Epana Bio is a biotechnology company headquartered in Berkeley, California, operating in the drug discovery sector. It develops precision therapies for autoimmune diseases by targeting cellular origins using genomics.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about dNovo? Suggest a correction · Work at dNovo? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.